Aimmune Therapeutics is a biopharmaceutical company focused on developing cures for food allergies. The company's Characterized Oral Desensitization (CODIT) approach is designed to protect patients from life-threatening allergic reactions caused by accidental food allergen exposure. Aimmune currently has one FDA-approved treatment for peanut allergy, and is also developing therapies for other food allergies. The company's goal is to become the global leader in food allergy treatments and improve the lives of people with food allergies.